Use of ipilimumab resulted in better rates of recurrence-free, overall, and distant metastasis–free survival compared with placebo in people with stage III melanoma in a randomized trial involving 951 individuals. Those who took the drug had more immune-related adverse events.
Patients had previously undergone complete resection, and were randomly assigned to receive ipilimumab 10 mg/kg (n=475) or placebo (n=476) every 3 weeks for 4 doses. They continued therapy every 3 months for up to 3 years. Among the results:
- The 5-year rate of recurrence-free survival was 41% in the ipilimumab group, vs 30% in the placebo cohort.
- Overall survival rates were 65% and 54%, respectively.
- Distant metastasis–free survival rates were 48% and 39%, respectively.
- Grade 3 or 4 adverse event rates were 54% and 26%, respectively.
- Grade 3 or 4 immune-related adverse event rates were 41% and 3%, respectively; 5 patients in the ipilimumab group died due to immune-related adverse events.
Eggermont A, Chiarion-Sileni V, Grob J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. [Published online ahead of print October 8, 2016]. N Engl J Med. doi:10.1056/NEJMoa1611299.
This Week's Must Reads
How do you pronounce that drug name?, Frank D. JAMA Intern Med. 2018;178(3):319-320. doi:10.1001/jamainternmed.2017.7898
'Glass ceiling' extends to biomedical industry payments, Tringale K and Hattangadi-Gluth J. JAMA Intern Med. 2018;178(3):421-423. doi:10.1001/jamainternmed.2017.7445
Mining social media to detect adverse drug reactions to newly-approved drugs, Ransohoff J et al. JAMA Oncology March 1, 2018. doi:10.1001/jamaoncol.2017.5688
Insurance type linked to cancer care delays, Wharam et al. J Clin Oncol. 2018 Feb 28. doi: 10.1200/JCO.2017.75.2501.
Intervention boosted the rate of colorectal cancer screening, Source: Miller, D et al. Ann Inter Med 2018. DOI: 10.7326/M17-2315
Must Reads in Melanoma
FDA Approves First Treatment for Rare Skin Cancer, FDA news release; 2017 Mar 23
High-Dose Interferon vs Observation for Melanoma , J Clin Oncol; ePub 2017 Jan 30; Agarwala, et al
Trends in US Melanoma Incidence and Mortality, JAMA Dermatol; ePub 2016 Dec 21; Glazer, et al
Ipilimumab’s Impact on Stage III Melanoma Evaluated , N Engl J Med; ePub 2016 Oct 8; Eggermont, et al
PD-1 Inhibitor–Related Pneumonitis Evaluated, JAMA Oncol; ePub 2016 Aug 18; Nishino, et al